Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib combined with camrelizumab as first-line treatment for advanced hepatocellular carcinoma
ChiCTR2000035161Phase 4Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib and camrelizumab in hepatocellular carcinoma (HCC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: overall survival. Started Aug 2021; status: recruiting.
02
Drugs
lenvatinibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000035161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035161.